06:44 AM EDT, 06/10/2024 (MT Newswires) -- Oculis Holding (OCS) said Monday it had detected favorable topline results from a phase 2b trial of licaminlimab for the treatment of patients with dry-eye disease.
The 122-patient study showed treatment effects "favoring" licaminlimab in multiple sign endpoints accepted by the US Food and Drug Administration.